Sandoz and Aequus Agree to 1-Year Extension on Vistitan in Canada

VANCOUVER, BC – Aequus Pharmaceuticals Inc. (TSX-V: AQS,OTCQB: AQSZF)(“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, is pleased to announce a 1-year extension of terms with Sandoz Canada Inc., with option for parties to renew, for promotional services related to Vistitan™(bimatoprost 0.03% ophthalmic solution). Vistitan eye drops are used to reduce elevated pressure in the eye inpatients with open-angle glaucoma or ocular hypertension.

“The contract extension recognizes a 4-year relationship that has seen Aequus’ commercial team consistently grow the Vistitan brand by >30%CAGR over that same period”, said Doug Janzen, CEO and Chairman of Aequus.

Grant Larsen, Chief Commercial Officer added, “This extension aligns with our mission to identify complementary and innovative products that provide value to patients and eye care professionals in Canada. We continue to invest in our team and capacity to scale up with additional strategic products and partners in the growing Canadian eye care market.”

ABOUT AEQUUS PHARMACEUTICALS INC.

Aequus Pharmaceuticals Inc. (TSX-V: AQS,OTCQB: AQSZF)is a growing specialty pharmaceutical company focused on developing and commercializing high quality, differentiated products. Aequus has grown its sales and marketing efforts to include several commercial products in ophthalmology and transplant. Aequus plans to build on its Canadian commercial platform through the launch of additional products that are either created internally or brought in through an acquisition or license; remaining focused on highly specialized therapeutic areas.

Vistitan™: Trademark owned or used under license by Sandoz Canada Inc.

‍Original source here.